Narcolepsy Treatment Market By Type of Disorder (Secondary Narcolepsy, Narcolepsy with Cataplexy, Narcolepsy Without Cataplexy), By Drugs (Amphetamines, Methylphenidate, Modafinil, MAO-B Inhibitors (Selegiline), Tricyclic Anti-Depressants (TCA), Selective Serotonin Reuptake Inhibitors (SSRI), Monoamine Oxidase Type-A (MAO-A) inhibitors), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Narcolepsy Treatment Market size was valued at USD 3.2 billion in 2023 and is poised to grow at a CAGR of 9.8% from 2024-2030. Narcolepsy is a lifelong sleeping disorder that makes you feel immensely tired sometimes with uncontrollable sudden sleep attacks in severe cases. It is a disabling condition that is characterized by three different symptoms such as excessive daytime cataplexy, sleepiness, and irresistible sleep episodes, fluctuating automatic behaviors. Narcolepsy generally begins between 15 to 25 years and it can be evident at any age.

The narcolepsy treatment market is untreated and undiagnosed in many cases. Narcolepsy is the 3rd most common sleeping disorder which affects a large group of the population. The prevalence rate of narcolepsy is substantially lower in Israel i.e. 1 in 500,000 people and considerably high in Japan i.e. 1 in 600 in comparison with U.S. according to the narcolepsy network. Narcolepsy is not curable but can be treated with drugs like dextroamphetamine, methylphenidate etc. to reduce sleep attacks. Mergers and acquisitions, collaborations, and expansions to untapped geographies are the growth strategies that are adopted by the market players to enhance market growth and to improve their product portfolio. Several voluntary organizations across the world such as Wake up Narcolepsy, Narcolepsy Network, American Sleep Association, and European Narcolepsy Network are actively involved in spreading awareness regarding sleeping disorders and their associated symptoms like EDS, sleep paralysis, and cataplexy.

Narcolepsy Treatment Market Key Developments:  
  • In January 2017, Jazz pharmaceuticals received U.S.FDA approval for the first generic version of Xyrem to treat narcolepsy patients.
  • In September 2016, Ligand Pharmaceuticals out-licenses 4 development programs to Seelos Therapeutics, that including its H3 receptor antagonist program for narcolepsy, Aplindore program for various CNS disorders, CRTH2 antagonist program for respiratory disorders, Captisol enabled acetaminophen program for fever and pain management. 

Global Narcolepsy Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

9.8%

Largest Market

North America

Fastest Growing Market

North America
Narcolepsy Treatment Market Dynamics

Factors that are driving the growth of Global Narcolepsy Treatment Market are growing prevalence of various sleeping disorders including narcolepsy, increase awareness about the sleep disorders. Furthermore, increasing demand for advanced diagnostics and therapeutics to treat sleeping disorders and rise in geriatric population. A narcoleptic disorder is proportionately prevalent to Parkinson’s disease, according to the WHO statistics, more than 3 million people are suffering from narcolepsy across the globe. However, stringent regulatory framework, unawareness about the disorder in underdeveloped countries, abuse usage of the drugs, delayed or undiagnosed of the narcolepsy are the few factors which are hampering the growth of narcolepsy treatment market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Narcolepsy Treatment Market Segmentation

By Type Of Disorder
  • Secondary Narcolepsy
  • Narcolepsy with cataplexy
  • Narcolepsy without cataplexy
By Drugs
  • Amphetamines
  • Methylphenidate
  • Modafinil
  • MAO-B Inhibitors (Selegiline)
  • Tricyclic Anti-Depressants (TCA)
  • Selective Serotonin Reuptake Inhibitors (SSRI)
  • Monoamine Oxidase Type-A (MAO-A) inhibitors
By Distribution Channel
  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The Narcolepsy Treatment Market size was valued at USD 3.2 billion in 2023

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

The narcolepsy treatment market key players are Arena Pharmaceuticals, Inc.(U.S) BIOPROJET Evotec AG (Germany) Graymark Healthcare, Inc. (U.S) Hypnion, Inc. (U.S) Ligand Pharmaceuticals, Inc.(U.S) Teva Pharmaceutical Industries Ltd.(Israel) Jazz Pharmaceuticals, Inc.,(Ireland)

1. Executive Summary
2. Global Narcolepsy Treatment Market Introduction 
2.1.Global Narcolepsy Treatment Market  - Taxonomy
2.2.Global Narcolepsy Treatment Market  - Definitions
2.2.1.Type Of Disorder
2.2.2.Drugs
2.2.3.Distribution Channel
2.2.4.Region
3. Global Narcolepsy Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Narcolepsy Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Narcolepsy Treatment Market  By Type Of Disorder, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Secondary Narcolepsy
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Narcolepsy with cataplexy
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Narcolepsy without cataplexy
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Narcolepsy Treatment Market  By Drugs, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Amphetamines
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Methylphenidate
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Modafinil
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. MAO-B Inhibitors (Selegiline)
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Tricyclic Anti-Depressants (TCA)
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
6.6. Selective Serotonin Reuptake Inhibitors (SSRI)
6.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.6.3. Market Opportunity Analysis 
6.7. Monoamine Oxidase Type-A (MAO-A) inhibitors
6.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.7.3. Market Opportunity Analysis 
7. Global Narcolepsy Treatment Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Hospital pharmacies
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Online Pharmacies
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8. Global Narcolepsy Treatment Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Narcolepsy Treatment Market,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Type Of Disorder Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Secondary Narcolepsy
9.1.2.Narcolepsy with cataplexy
9.1.3.Narcolepsy without cataplexy
9.2.  Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Amphetamines
9.2.2.Methylphenidate
9.2.3.Modafinil
9.2.4.MAO-B Inhibitors (Selegiline)
9.2.5.Tricyclic Anti-Depressants (TCA)
9.2.6.Selective Serotonin Reuptake Inhibitors (SSRI)
9.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors
9.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital pharmacies
9.3.2.Retail Pharmacies
9.3.3.Online Pharmacies
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10. Europe Narcolepsy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Type Of Disorder Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Secondary Narcolepsy
10.1.2.Narcolepsy with cataplexy
10.1.3.Narcolepsy without cataplexy
10.2.  Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Amphetamines
10.2.2.Methylphenidate
10.2.3.Modafinil
10.2.4.MAO-B Inhibitors (Selegiline)
10.2.5.Tricyclic Anti-Depressants (TCA)
10.2.6.Selective Serotonin Reuptake Inhibitors (SSRI)
10.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors
10.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital pharmacies
10.3.2.Retail Pharmacies
10.3.3.Online Pharmacies
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Narcolepsy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Type Of Disorder Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Secondary Narcolepsy
11.1.2.Narcolepsy with cataplexy
11.1.3.Narcolepsy without cataplexy
11.2.  Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Amphetamines
11.2.2.Methylphenidate
11.2.3.Modafinil
11.2.4.MAO-B Inhibitors (Selegiline)
11.2.5.Tricyclic Anti-Depressants (TCA)
11.2.6.Selective Serotonin Reuptake Inhibitors (SSRI)
11.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors
11.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital pharmacies
11.3.2.Retail Pharmacies
11.3.3.Online Pharmacies
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12. Middle East and Africa (MEA) Narcolepsy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Type Of Disorder Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Secondary Narcolepsy
12.1.2.Narcolepsy with cataplexy
12.1.3.Narcolepsy without cataplexy
12.2.  Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Amphetamines
12.2.2.Methylphenidate
12.2.3.Modafinil
12.2.4.MAO-B Inhibitors (Selegiline)
12.2.5.Tricyclic Anti-Depressants (TCA)
12.2.6.Selective Serotonin Reuptake Inhibitors (SSRI)
12.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors
12.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital pharmacies
12.3.2.Retail Pharmacies
12.3.3.Online Pharmacies
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Narcolepsy Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Type Of Disorder Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Secondary Narcolepsy
13.1.2.Narcolepsy with cataplexy
13.1.3.Narcolepsy without cataplexy
13.2.  Drugs Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Amphetamines
13.2.2.Methylphenidate
13.2.3.Modafinil
13.2.4.MAO-B Inhibitors (Selegiline)
13.2.5.Tricyclic Anti-Depressants (TCA)
13.2.6.Selective Serotonin Reuptake Inhibitors (SSRI)
13.2.7.Monoamine Oxidase Type-A (MAO-A) inhibitors
13.3.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital pharmacies
13.3.2.Retail Pharmacies
13.3.3.Online Pharmacies
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Arena Pharmaceuticals, Inc.(U.S)
14.2.2.BIOPROJET
14.2.3.Evotec AG (Germany)
14.2.4.Graymark Healthcare, Inc. (U.S)
14.2.5.Hypnion, Inc. (U.S)
14.2.6.Ligand Pharmaceuticals, Inc.(U.S)
14.2.7.Teva Pharmaceutical Industries Ltd.(Israel)
14.2.8.Jazz Pharmaceuticals, Inc.,(Ireland)
15. Research Methodology
  • Arena Pharmaceuticals, Inc.(U.S)
  • BIOPROJET
  • Evotec AG (Germany)
  • Graymark Healthcare, Inc. (U.S)
  • Hypnion, Inc. (U.S)
  • Ligand Pharmaceuticals, Inc.(U.S)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Jazz Pharmaceuticals, Inc.,(Ireland)

Adjacent Markets